Panitumumab companion diagnostic - Amgen/Biocartis

Drug Profile

Panitumumab companion diagnostic - Amgen/Biocartis

Alternative Names: IdyllaTM KRAS mutation test; IdyllaTM NRAS-BRAF mutation test

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocartis
  • Developer Amgen; Biocartis
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Colorectal cancer

Most Recent Events

  • 04 Dec 2017 Biocartis entered into an agreement with Amgen to develop Idylla™ RAS biomarker tests for Colorectal cancer
  • 04 Dec 2017 Early research in Colorectal cancer (Diagnosis, Metastatic disease) in USA (unspecified route)
  • 04 Dec 2017 Biocartis intends to pursue a premarket approval (PMA4) for the Idylla™ KRAS mutation test and the Idylla™ NRAS-BRAF mutation test with the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top